AI drug discovery startup Peptris raised $1 M Pre-seed funding from Speciale Invest
The pre-seed round of AI drug discovery startup Peptris, led by Speciale Invest, has raised $1 million.
According to a press release from Peptris, the funds will be utilized to boost the company’s efforts in the drug research and discovery arena to advance AI-driven solutions. Its main goal will be to develop novel therapies for unreachable targets, particularly in the fields of oncology, inflammation, and rare diseases.
Peptris, founded by Amit Mahajan, Anand Budni, and Narayanan Venkatasubramanian, has created a computational platform based on AI/ML to speed up the search for new drugs.
The business shortens the time required for laboratory testing by efficiently sifting through enormous data sets to find and create potential new drugs.
AI’s application to drug discovery tackles more than 7,000 known conditions for which there are no approved treatments, especially when it comes to rare diseases.
Disclaimer: A group of investors recently provided funding to Bareback Media. Some investors might be connected to other businesses we might write about, or they might be directly or indirectly involved in a rival company. That being said, this will not in any way affect our coverage or reporting. A list of our investors is available.
